Research Papers:

Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?

Yeqing Mao _, Xin Xu, Xiao Wang, Xiangyi Zheng and Liping Xie

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:6765-6773. https://doi.org/10.18632/oncotarget.6837

Metrics: PDF 1846 views  |   HTML 2347 views  |   ?  


Yeqing Mao1, Xin Xu1, Xiao Wang1, Xiangyi Zheng1 and Liping Xie1

1 Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Correspondence to:

Yeqing Mao, email:

Xin Xu, email:

Keywords: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, prostate cancer, meta-analysis, cohort

Received: September 09, 2015 Accepted: January 01, 2016 Published: January 07, 2016


Emerging evidence suggests that renin-angiotensin system (RAS) may act as a molecular and therapeutic target for treating site-specific cancers, including prostate cancer. However, previous observational studies regarding the association between RAS inhibitors and prostate cancer risk have reported inconsistent results. We examined this association by performing a systematic review and meta-analysis. A total of 20,267 patients from nine cohort studies were enrolled. Compared with non-users of RAS inhibitors, individuals using RAS inhibitors had a reduced risk of prostate cancer (RR 0.92, 95 % CI 0.87-0.98), without statistically significant heterogeneity among studies (P = 0.118 for heterogeneity, I2 = 37.6 %). In addition, when subgroup analyses by study quality and number of cases, more statistically significant associations were observed in studies of high quality (RR 0.93, 95 % CI 0.88-0.97) and large sample size (RR 0.94, 95 % CI 0.91-0.98). There was no evidence of significant publication bias with Begg’s test (P = 0.602) or with Egger’s test (P = 0.350). Overall, this study indicates that use of RAS inhibitors may be associated with a decreased risk of prostate cancer. Large-scale well designed studies are needed to further explore this association.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6837